Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin and GABA levels in ASD
NCT03589898Phase 1Completed
- Sponsor
- University of Massachusetts
- Start
- Sep 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gabapentin in Autism Spectrum Disorder (ASD), sponsored by University of Massachusetts. Primary endpoints: Cortical GABA in Anterior Cingulate Cortex at 6 hours and Cortical GABA in Right Anterior Insula at 6 hours. Started Sep 2017; status: completed.
02
Drugs
gabapentin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03589898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589898.